Drug Profile
AM 365
Latest Information Update: 14 Aug 2002
Price :
$50
*
At a glance
- Originator Zenyth Therapeutics
- Class Antivirals; Nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 11 Jul 2002 Discontinued - Phase-II for Hepatitis B in Australia (unspecified route)
- 22 Mar 2001 Phase-II clinical trials for Hepatitis B in Australia (Unknown route)
- 05 Oct 2000 Phase I trials have been completed